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ABSTRACT  
The PTEN tumour suppressor is the second most frequently mutated tumour suppressor gene 
in cancer. It is a lipid and protein phosphatase that negatively regulates the well-known pro-
proliferative and anti-apoptotic phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway to 
modulate cell proliferation, cell cycle progression and cell survival. Sphingosine kinase 1 (SphK1), 
a known tumour promoter/oncogene, has been shown to activate the PI3K/Akt pathway to 
enhance resistance to apoptosis. The loss of function of PTEN and/or the overexpression of 
SphK1 contribute to tumorigenesis. This thesis describes the analysis of novel, cancer associated 
mutations of PTEN, to determine their effect(s) on wild type (WT) PTEN function, and also 
explores differential SphK1 isoform expression in cancers.  
Previous work in our laboratory described 10 novel somatic mutations of PTEN in primary 
colorectal tumours. To determine the functional consequences of these novel cancer-
associated PTEN mutations, the WT PTEN and the series of PTEN mutants (K62R, Y65C, K125E, 
K125X, E150Q, D153N, D153Y, N323K and the C124S and G129E controls) were transiently 
transfected into: (A) PTEN null U87MG glioblastoma cells, and WT PTEN expressing (A) HCT116 
colon cancer and (C) MCF7 breast cancer cells. Transfected cells were then assayed for cell 
proliferation, cell cycle phase distribution and AKT phosphorylation. In U87MG cells, 50% of 
the PTEN mutants (Y65C, K125E, E150Q and D153Y) exhibited statistically significant reductions 
in cell proliferation, but not to the level of that of WT PTEN. In both the HCT116 and MCF7 cell 
lines, 80% of the PTEN mutants (K62R, Y65C, K125E, K125X, E150Q, D153Y and N323K) 
displayed reduced cell proliferation rates but none produced reductions comparable with WT 
PTEN. Further, relative to WT PTEN, 75% of PTEN mutants (K62R, K125X, E150Q, D153N and 
N323K) possessed functional deficiency in cell cycle inhibitory capacity in the G2 phase in 
U87MG cells. In contrast, 90% of PTEN mutants (K62R, K125E, K125X, E150Q, D153N, D153Y 
and N323K) possessed functional deficiency in the cell cycle inhibitory capacity in either the G1 
or G2 phase in HCT116 cells. In MCF7 cells, 100% and 60% (K62R, Y65C, D153N, D153Y and 
N323K) of the PTEN mutants had functional deficiency in cell cycle inhibitory capacity in either 
the G1 or G2 phase, respectively. The analyses of endogenous suppression of phosphorylation 
of AKT revealed that 40% of PTEN mutants (K125E, K125X and D153N) show deficiency in pAKT 
suppression in the U87MG cell line while 60% of the mutants showed such deficiency in the 
HCT116 cell line (K125X, E150Q, D153N, D153Y and N323K). All but one (K62R) of the PTEN 
mutants showed a deficiency in the ability to suppress the level of endogenous phosphorylated 
AKT in the MCF7 cells. Overall, the results of the functional assays showed that the somatic 
mutations of the PTEN gene alter PTEN tumour suppressor function. 
Expression of SphK1, a positive upstream regulator of the Akt pathway, is expressed as 2 major 
isoforms, SphK1-43kDa (SphK1a) and SphK1-51kDa (SphK1b), with similar SphK1 activity. 
However, to date, there is no literature on the expression of the two SphK1 isoforms in cell 
lines or human tissues. Profiling the expression of the two SphK isoforms in various cancer cell 
lines (n=24), primary cancer tissues (n=28) and paired adjacent tissues (n=28), demonstrated 
that the SphK1a isoform is expressed in all cell lines and tissues (both normal and cancer) 
studied, however, expression of SphK1b is cell and tissue specific, including breast, prostate 
and lung. Balancing signalling pathways and maintaining cellular homeostasis, as observed 
through the PTEN/SphK1 swinging pendulum is important and the study of these pathways is 
crucial in gaining further understanding the opposing regulatory mechanisms, which may be 
exploited for the future prevention and treatment of cancers. 
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